Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesAsset Writedowns and ImpairmentCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in CashChange in InventoryChange in ReceivablesDepreciation & Amortization (CF)Exchange Rate EffectFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeNon-cash ItemsOther Working Capital ChangesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Tonix Pharmaceuticals Holding (TNXP) Gains from Investment Securities: 2023-2025

Historic Gains from Investment Securities for Tonix Pharmaceuticals Holding (TNXP) over the last 3 years, with Sep 2025 value amounting to $1.2 million.

  • Tonix Pharmaceuticals Holding's Gains from Investment Securities rose 225.08% to $1.2 million in Q3 2025 from the same period last year, while for Sep 2025 it was $1.2 million, marking a year-over-year increase of 225.08%. This contributed to the annual value of $3,865 for FY2024, which is 399.35% up from last year.
  • As of Q3 2025, Tonix Pharmaceuticals Holding's Gains from Investment Securities stood at $1.2 million, which was up 0.34% from $1.2 million recorded in Q2 2025.
  • Tonix Pharmaceuticals Holding's Gains from Investment Securities' 5-year high stood at $9.7 million during Q1 2024, with a 5-year trough of $774 in Q4 2023.
  • Over the past 3 years, Tonix Pharmaceuticals Holding's median Gains from Investment Securities value was $1.2 million (recorded in 2025), while the average stood at $2.5 million.
  • Over the last 5 years, Tonix Pharmaceuticals Holding's Gains from Investment Securities had its largest YoY gain of 225.08% in 2025, and its largest YoY loss of 93.09% in 2025.
  • Over the past 3 years, Tonix Pharmaceuticals Holding's Gains from Investment Securities (Quarterly) stood at $774 in 2023, then tumbled by 74.27% to $356,173 in 2024, then surged by 225.08% to $1.2 million in 2025.
  • Its Gains from Investment Securities stands at $1.2 million for Q3 2025, versus $1.2 million for Q2 2025 and $674,134 for Q1 2025.